Progressive and incurable, Alzheimer’s disease affects an estimated 6.7 million U.S. adults at least 65 years old, according ...

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time. Those medications, however, are not without their risks and side effects.

Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...

Alzheimer's patients with a baseline CDR-SB score of 3.5 could expect approximately 4 additional months (95% CI 2-7 months) ...

BioArctic signed the first deal for its “brain transporter” with Bristol Myers Squibb late last year. The deal is worth up to $1.4bn and allows the US drugmaker to start trials using the technology to ...

Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...

The Western New York Chapter of the Alzheimer’s Association will offer two free programs in the area next week — one on ...

Imagine you have just been diagnosed with mild cognitive decline due to Alzheimer’s disease ... daily activities without ...

Eisai announces Leqembi sales reaches €200 million; BioArctic to receive €10 million payment: Stockholm, Sweden Wednesday, February 19, 2025, 14:00 Hrs [IST] BioArctic AB’s ...

The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement has been reached. The milestone was reached as ...